The groundbreaking success of Viagra undeniably revolutionized the pharmaceutical landscape, but placing funds in companies primarily reliant on unbranded versions presents a complex picture. While early profits were substantial, the cessation of patents and the rise of less expensive alternatives have weakened the customer base. Thus, a thorough a